ArticleActa pharmaceutica Sinica. B2022

Erratum: Author correction to "Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers" [Acta Pharmaceutica Sinica B 11 (2021) 355-372].

Tingting Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.